The oral peptide company

A novel approach to treat type 2 diabetes and its co-morbidities

 

Key facts about
Enterosys.

Innovation in the field of metabolic disease

By 2040 more than 640 million people impacted of which ~90% have T2 diabetes.

Scientist founders are international experts of the gut-brain axis

Internationally acknowledged in the field of microbiota and gut-brain axis in the control of glycemia.

 

Orally deliverable peptides

An upstream regulator of glycaemia leading to systemic physiological effect. A local effect for a remote control strategy.

Identification through validated OMICS strategies of innovative therapeutic peptides and targets.